SpliceBio, S.L.

SpliceBio already had the backing from the venture arms of two pharma companies – UCB and Novartis – and two other big players in the industry have participated in an impressive second funding round f

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

In a biopharma ecosystem with reduced cash flow, even established companies must focus more on demonstrating their unique value proposition. Companies of all sizes are concentrating on how to “show in

While most biotechs struggle amid a prolonged funding winter, one group is doing just fine. We are not talking about artificial intelligence. Several start-ups working on nucleic acid-based therapies